Analytical Data
-
Gene name
C2
- Application
-
Alternative Names
C2；C2 domain-containing Protein 3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P07910
-
Expression Region
1-293aa
-
AA Sequence
MGSSHHHHHHSSGLVPRGSHMASNVTNKTDPRSMNSRVFIGNLNTLVVKK SDVEAIFSKYGKIVGCSVHKGFAFVQYVNERNARAAVAGEDGRMIAGQVL DINLAAEPKVNRGKAGVKRSAAEMYGSSFDLDYDFQRDYYDRMYSYPARV PPPPPIARAVVPSKRQRVSGNTSRRGKSGFNSKSGQRGSSKSGKLKGDDL QAIKKELTQIKQKVDSLLENLEKIEKEQSKQAVEMKNDKSEEEQSSSSVK KDETNVKMESEGGADDSAEEGDLLDDDDNEDRGDDQLELIKDDEKEAEEG EDDRDSANGEDDS
-
Molecular Weight
35 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
C2 recombinant proteins have gained significant attention in biomedical research due to their diverse applications in drug development, vaccine production, and therapeutic protein engineering. The C2 domain, originally identified in certain bacterial toxins and mammalian proteins, plays a crucial role in calcium-dependent membrane interactions and cellular signaling. Researchers have harnessed the unique properties of the C2 domain to create recombinant proteins that can effectively target specific biomolecules or pathways. This is particularly valuable in the development of targeted therapies for various diseases, including cancer and autoimmune disorders. Additionally, C2 recombinant proteins are being explored for their potential in enhancing vaccine efficacy by serving as adjuvants, facilitating stronger immune responses. As techniques in genetic engineering and protein expression continue to advance, the generation of C2 recombinant proteins with enhanced functionality and specificity is becoming increasingly feasible. This progression opens new avenues for innovative therapeutic strategies and diagnostics, marking a significant step forward in the field of molecular biology and medicine.
